Epilepsy
0.320
Biomarker
disease
BEFREE
SLC4A10 is the third SLC4 base transporter family member to be implicated in human cognition and epilepsy .
18413482
2008
Epilepsy
0.320
Therapeutic
disease
CTD_human
Hence, Slc4a10 is a promising pharmacological target for the therapy of epilepsy or elevated intracranial pressure.
18165320
2008
Intellectual Disability
0.310
Biomarker
group
BEFREE
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation .
18413482
2008
Intellectual Disability
0.310
Biomarker
group
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation .
18413482
2008
Cognition Disorders
0.300
Biomarker
group
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Profound Mental Retardation
0.300
Biomarker
disease
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Mental Retardation, Psychosocial
0.300
Biomarker
phenotype
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Epilepsy, Frontal Lobe
0.300
Biomarker
disease
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Epilepsy, Cryptogenic
0.300
Therapeutic
disease
CTD_human
Mice with targeted Slc4a10 gene disruption have small brain ventricles and show reduced neuronal excitability.
18165320
2008
Intracranial Hypertension
0.300
Therapeutic
disease
CTD_human
Hence, Slc4a10 is a promising pharmacological target for the therapy of epilepsy or elevated intracranial pressure .
18165320
2008
×
CUI:
C0236018
Disease:
Aura
Aura
0.300
Therapeutic
phenotype
CTD_human
Mice with targeted Slc4a10 gene disruption have small brain ventricles and show reduced neuronal excitability.
18165320
2008
Frontal Epilepsy, Benign, Childhood
0.300
Biomarker
disease
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Epilepsy, Supplementary Motor
0.300
Biomarker
disease
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Epilepsy, Cingulate
0.300
Biomarker
disease
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Epilepsy, Opercular
0.300
Biomarker
disease
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Awakening Epilepsy
0.300
Therapeutic
disease
CTD_human
Mice with targeted Slc4a10 gene disruption have small brain ventricles and show reduced neuronal excitability.
18165320
2008
Epilepsy, Anterior Fronto-Polar
0.300
Biomarker
disease
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Epilepsy, Orbito-Frontal
0.300
Biomarker
disease
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Mental deficiency
0.300
Biomarker
disease
CTD_human
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Mental Retardation
0.010
Biomarker
disease
BEFREE
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation .
18413482
2008
Epilepsy, Complex Partial
0.010
Biomarker
disease
BEFREE
Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.
18413482
2008
Epilepsy
0.320
Biomarker
disease
BEFREE
This second region comprises about 3 Mb and contains the candidate gene SLC4A10 , providing further support for the potential role of this gene in epilepsy .
21204806
2010
Glaucoma, Primary Open Angle
0.010
GeneticVariation
disease
BEFREE
There was no association between common sequence variants in the AQP1 or SLC4A10 genes and POAG in the Caucasian population.
20101282
2010
Mental Depression
0.010
Biomarker
disease
BEFREE
Six genes were identified as of interest for a follow-up, based on the strength of the association and based on the interest as potential candidate target for developing new treatment for depression : Solute Carrier Family 4 Member 10 (SLC4A10 ), Dipeptidyl Peptidase IV (DPP4), Dopamine Receptor D3 (DRD3), Zinc Finger Protein 80 (ZNF80), Nitric Oxide Synthase 2A (NOS2A) and Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1, Alpha (PPARGC1A).
21630437
2011
Depressive disorder
0.010
Biomarker
disease
BEFREE
Six genes were identified as of interest for a follow-up, based on the strength of the association and based on the interest as potential candidate target for developing new treatment for depression : Solute Carrier Family 4 Member 10 (SLC4A10 ), Dipeptidyl Peptidase IV (DPP4), Dopamine Receptor D3 (DRD3), Zinc Finger Protein 80 (ZNF80), Nitric Oxide Synthase 2A (NOS2A) and Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1, Alpha (PPARGC1A).
21630437
2011